SUA aprobă primul vaccin antigripal pe bază de ARNm pentru persoanele de peste 50 de ani

The FDA has approved the first mRNA flu vaccine for adults aged 50 and older, developed by Moderna. This vaccine shows 27% higher efficacy than standard flu vaccines. It allows for quicker adaptation to circulating flu strains, potentially improving immunity. Adverse reactions include injection site pain and fatigue. Despite initial hesitations, an independent advisory committee unanimously supported its benefits. The vaccine is expected to be available this fall.